Takip et
Eyad Elkord
Eyad Elkord
Professor; Dept of Biosciences&Bioinformatics-School of Science-XJTLU; Uni of Salford; Abu Dhabi Uni
xjtlu.edu.cn üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Immune checkpoint inhibitors: recent progress and potential biomarkers
P Darvin, SM Toor, V Sasidharan Nair, E Elkord
Experimental & molecular medicine 50 (12), 1-11, 2018
21382018
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
DS Vinay, EP Ryan, G Pawelec, WH Talib, J Stagg, E Elkord, T Lichtor, ...
Seminars in cancer biology 35, S185-S198, 2015
18782015
Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity
A Jaggupilli, E Elkord
Journal of Immunology Research 2012 (1), 708036, 2012
6422012
Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting
B Chaudhary, E Elkord
Vaccines 4 (3), 28, 2016
5522016
Designing a broad-spectrum integrative approach for cancer prevention and treatment
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35, S276-S304, 2015
3252015
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
V Sasidharan Nair, E Elkord
Immunology & Cell Biology 96 (1), 21-33, 2018
3162018
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma
C Ralph, E Elkord, DJ Burt, JF O'Dwyer, EB Austin, PL Stern, RE Hawkins, ...
Clinical Cancer Research 16 (5), 1662-1672, 2010
3012010
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
S Daayana, E Elkord, U Winters, M Pawlita, R Roden, PL Stern, ...
British journal of cancer 102 (7), 1129-1136, 2010
2872010
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
R Saleh, E Elkord
Cancer letters 490, 174-185, 2020
2832020
Neuropilin 1: function and therapeutic potential in cancer
B Chaudhary, YS Khaled, BJ Ammori, E Elkord
Cancer Immunology, Immunotherapy 63, 81-99, 2014
2592014
Myeloid‐derived suppressor cells in cancer: recent progress and prospects
YS Khaled, BJ Ammori, E Elkord
Immunology and cell biology 91 (8), 493-502, 2013
2502013
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
RW Griffiths, E Elkord, DE Gilham, V Ramani, N Clarke, PL Stern, ...
Cancer Immunology, Immunotherapy 56, 1743-1753, 2007
2412007
T‐cell responses and therapies against SARS‐CoV‐2 infection
SM Toor, R Saleh, V Sasidharan Nair, RZ Taha, E Elkord
Immunology 162 (1), 30-43, 2021
2322021
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
R Saleh, E Elkord
Seminars in cancer biology 65, 13-27, 2020
2302020
Immune checkpoints in the tumor microenvironment
SM Toor, VS Nair, J Decock, E Elkord
Seminars in cancer biology 65, 1-12, 2020
2252020
Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells
E Elkord, PE Williams, H Kynaston, AW Rowbottom
Immunology 114 (2), 204-212, 2005
2182005
Treg-mediated acquired resistance to immune checkpoint inhibitors
R Saleh, E Elkord
Cancer letters 457, 168-179, 2019
2102019
Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19
H Shaath, R Vishnubalaji, E Elkord, NM Alajez
Cells 9 (11), 2374, 2020
1972020
Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients
YS Khaled, BJ Ammori, E Elkord
Journal of Immunology Research 2014, 9, 2014
1642014
T regulatory cells in cancer: recent advances and therapeutic potential
E Elkord, EM Alcantar-Orozco, SJ Dovedi, DQ Tran, RE Hawkins, ...
Expert opinion on biological therapy 10 (11), 1573-1586, 2010
1472010
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20